MHRA Class 3 Medicines Recall: Tropicamide 1% Eye Drops, solution in single dose containers 20 x 0.5ml (Aspire Pharma Limited)
MHRA Class 3 Medicines Recall: Tropicamide 1% Eye Drops, solution in single dose containers 20 x 0.5ml (Aspire Pharma Limited)
Drug Alert Number: EL(26)A/47
Date issued: 4 November 2026
Aspire Pharma Ltd is recalling specific batches of Tropicamide 1% Eye Drops, solution in single dose containers 0.5ml x 20, due to them being labelled with the incorrect expiry date. The correct expiry date for these batches should be 31/10/2026.
Marketing Authorisation Holder: Aspire Pharma Ltd
Medicine Details
Product name: Tropicamide 1% Eye Drops, solution in single dose containers 20 x 0.5ml
PL: 35533/0198
Active ingredient: tropicamide
SNOMED code: 45542111000001107
GTIN: 5060209733661
Affected Lot Batch Numbers
| Batch number | Expiry date | Pack size | First distributed |
| E941A | 30/04/2027* | 20 | 29/10/2025 |
| E941B | 30/04/2027* | 20 | 04/02/2026 |
| E941C | 30/04/2027* | 20 | 20/02/2026 |
*Incorrect expiry date printed on packs
Background
Aspire Pharma Ltd is recalling the above specific batches of Tropicamide 1% Eye Drops, solution in single dose containers 0.5ml x 20, due to them being labelled with the incorrect expiry date. The correct expiry date for these batches should be 31/10/2026.
Advice for Healthcare Professionals
Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
View the full alert here.
Advice for Patients
No further action is required by patients. This recall is being undertaken as a precautionary measure at the Pharmacy and Wholesaler level.
Patients in possession of these batches should continue to use the eye drops and contact their prescriber to obtain a replacement prescription. No reports of adverse incidents due to this defect have been received to date.
Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.
Additional information
For all medical information enquiries and information on this product, please email medinfo@aspirepharma.com, or telephone 01730 231148.
For stock control enquiries please email customerservices@aspirepharma.com, or telephone 01730 231148.





